Stock listing
NYSE:ANVS Annovis Bio, Inc. Stock
Home listing (NYSE) of Annovis Bio, Inc.
Follow Annovis Bio, Inc. into a list and get an email when it puts out news.
Share price · NYSE:ANVS
$0.711 USD -0.130 (-15.4%)
Close on Nov 20, 2026
- Day range
- $0.700 – $0.774 USDNov 20, 2026
- Volume
- 1.43M sharesNov 20, 2026
- Market cap
- $44.12M USDAt the close on Nov 20, 2026 · price × 62.02M shares outstanding
- 52-week range
- $0.620 – $5.500 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.75M USDMedian day 850,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:ANVS · Home | $0.711 USD | -0.130 (-15.4%) | 1,427,413 | $0.750 | $0.774 | $0.700 | $0.841 | Close on Nov 20, 2026 |
| Frankfurt:07X | €0.662 EUR | -0.086 (-11.5%) | — | €0.662 | €0.662 | €0.662 | €0.748 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ANVS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.711 | -0.130 | -15.4% | $0.750 | $0.774 | $0.700 | 1,427,413 | |
| $0.841 | +0.098 | +13.2% | $0.768 | $0.841 | $0.743 | 1,306,273 | |
| $0.743 | -0.007 | -0.9% | $0.824 | $0.824 | $0.702 | 1,884,604 | |
| $0.750 | -0.176 | -19.0% | $0.910 | $0.920 | $0.750 | 2,180,078 | |
| $0.926 | +0.079 | +9.3% | $0.885 | $0.950 | $0.818 | 2,162,086 | |
| $0.847 | -0.006 | -0.7% | $0.850 | $0.897 | $0.822 | 1,163,973 | |
| $0.853 | -0.021 | -2.4% | $0.873 | $0.873 | $0.793 | 1,619,169 | |
| $0.874 | -0.027 | -3.0% | $0.900 | $0.900 | $0.811 | 1,640,861 | |
| $0.901 | +0.061 | +7.3% | $0.940 | $0.990 | $0.830 | 5,192,451 | |
| $0.840 | +0.170 | +25.4% | $0.700 | $0.850 | $0.630 | 11,378,100 | |
| $0.670 | -0.540 | -44.6% | $0.880 | $0.910 | $0.620 | 30,867,700 | |
| $1.210 | +0.120 | +11.0% | $1.120 | $1.250 | $1.100 | 1,433,300 | |
| $1.090 | +0.010 | +0.9% | $1.070 | $1.150 | $1.060 | 681,400 | |
| $1.080 | -0.050 | -4.4% | $1.170 | $1.400 | $1.050 | 3,010,100 | |
| $1.130 | +0.110 | +10.8% | $1.020 | $1.170 | $1.010 | 1,499,400 | |
| $1.020 | 0.000 | 0.0% | $1.010 | $1.050 | $1.000 | 1,482,500 | |
| $1.020 | +0.020 | +2.0% | $0.980 | $1.030 | $0.980 | 911,400 | |
| $1.000 | +0.040 | +4.2% | $0.950 | $1.030 | $0.950 | 912,800 | |
| $0.960 | -0.040 | -4.0% | $1.000 | $1.000 | $0.930 | 593,000 | |
| $1.000 | +0.010 | +1.0% | $0.990 | $1.010 | $0.960 | 315,800 | |
| $0.990 | 0.000 | 0.0% | $0.990 | $1.050 | $0.980 | 448,400 | |
| $0.990 | +0.012 | +1.2% | $1.000 | $1.040 | $0.990 | 546,300 | |
| $0.978 | +0.018 | +1.9% | $0.960 | $1.040 | $0.960 | 703,977 | |
| $0.960 | -0.030 | -3.0% | $0.995 | $1.040 | $0.950 | 641,350 | |
| $0.990 | -0.060 | -5.7% | $1.060 | $1.080 | $0.990 | 641,400 | |
| $1.050 | +0.030 | +2.9% | $1.040 | $1.080 | $1.010 | 572,200 | |
| $1.020 | -0.040 | -3.8% | $1.050 | $1.080 | $1.010 | 844,200 | |
| $1.060 | -0.090 | -7.8% | $1.150 | $1.150 | $1.050 | 850,800 | |
| $1.150 | -0.060 | -5.0% | $1.210 | $1.210 | $1.140 | 460,200 | |
| $1.210 | +0.040 | +3.4% | $1.170 | $1.240 | $1.140 | 521,900 | |
| $1.170 | -0.040 | -3.3% | $1.210 | $1.210 | $1.140 | 815,400 | |
| $1.210 | +0.030 | +2.5% | $1.170 | $1.230 | $1.160 | 429,700 | |
| $1.180 | -0.020 | -1.7% | $1.200 | $1.240 | $1.170 | 538,700 | |
| $1.200 | +0.020 | +1.7% | $1.160 | $1.200 | $1.140 | 657,600 | |
| $1.180 | +0.010 | +0.9% | $1.190 | $1.200 | $1.140 | 648,500 | |
| $1.170 | -0.100 | -7.9% | $1.270 | $1.280 | $1.160 | 1,201,800 | |
| $1.270 | -0.030 | -2.3% | $1.300 | $1.340 | $1.270 | 572,500 | |
| $1.300 | -0.080 | -5.8% | $1.390 | $1.410 | $1.300 | 812,000 | |
| $1.380 | +0.070 | +5.3% | $1.320 | $1.430 | $1.300 | 1,190,000 | |
| $1.310 | -0.020 | -1.5% | $1.350 | $1.360 | $1.310 | 573,500 | |
| $1.330 | +0.060 | +4.7% | $1.270 | $1.340 | $1.230 | 853,900 | |
| $1.270 | +0.010 | +0.8% | $1.300 | $1.330 | $1.240 | 1,144,300 | |
| $1.260 | +0.070 | +5.9% | $1.190 | $1.300 | $1.190 | 1,214,700 | |
| $1.190 | +0.050 | +4.4% | $1.160 | $1.220 | $1.160 | 882,300 | |
| $1.140 | +0.040 | +3.6% | $1.120 | $1.160 | $1.090 | 677,900 | |
| $1.100 | +0.060 | +5.8% | $1.100 | $1.170 | $1.080 | 1,521,800 | |
| $1.040 | -0.080 | -7.1% | $1.120 | $1.130 | $1.040 | 1,431,100 | |
| $1.120 | -0.020 | -1.8% | $1.140 | $1.140 | $1.100 | 823,200 | |
| $1.140 | +0.020 | +1.8% | $1.100 | $1.170 | $1.100 | 1,201,700 | |
| $1.120 | -0.070 | -5.9% | $1.200 | $1.230 | $1.100 | 1,893,400 | |
| $1.190 | -0.030 | -2.5% | $1.210 | $1.260 | $1.170 | 1,337,500 | |
| $1.220 | -0.080 | -6.2% | $1.310 | $1.320 | $1.220 | 1,743,600 | |
| $1.300 | -0.090 | -6.5% | $1.390 | $1.400 | $1.300 | 1,962,800 | |
| $1.390 | +0.010 | +0.7% | $1.400 | $1.440 | $1.380 | 1,532,600 | |
| $1.380 | -0.320 | -18.8% | $1.650 | $1.680 | $1.320 | 7,332,100 | |
| $1.700 | +0.010 | +0.6% | $1.710 | $1.760 | $1.690 | 606,800 | |
| $1.690 | -0.030 | -1.7% | $1.730 | $1.730 | $1.670 | 457,200 | |
| $1.720 | 0.000 | 0.0% | $1.720 | $1.780 | $1.700 | 425,500 | |
| $1.720 | -0.090 | -5.0% | $1.780 | $1.830 | $1.710 | 498,400 | |
| $1.810 | +0.030 | +1.7% | $1.760 | $1.810 | $1.760 | 292,300 | |
| $1.780 | -0.040 | -2.2% | $1.840 | $1.860 | $1.760 | 233,600 | |
| $1.820 | +0.070 | +4.0% | $1.760 | $1.825 | $1.760 | 560,283 | |
| $1.750 | -0.070 | -3.8% | $1.830 | $1.830 | $1.740 | 670,723 | |
| $1.820 | +0.030 | +1.7% | $1.780 | $1.840 | $1.770 | 618,600 | |
| $1.790 | -0.060 | -3.2% | $1.840 | $1.890 | $1.780 | 548,800 |
- Ticker
- NYSE:ANVS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
Latest deck · Jan 28, 2026
Corporate Update (January 2026)
Corporate update · 26 slides
Latest news
Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
Nov 20, 2026
Closed $0.711 (-15.4%) on Nov 20, 2026
Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
Nov 17, 2026
Closed $0.743 (-0.9%) on Nov 17, 2026
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Nov 13, 2026
Closed $0.926 (+9.3%) on Nov 13, 2026
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Nov 12, 2026
Closed $0.847 (-0.7%) on Nov 12, 2026
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Nov 9, 2026
Closed $0.901 (+7.3%) on Nov 9, 2026
Annovis Announces Pricing of $21.0 Million Public Offering
Nov 5, 2026
Closed $0.67 (-44.6%) on Nov 5, 2026
Annovis Announces Launch of Proposed Public Offering
Nov 4, 2026
Closed $0.67 (-44.6%) on Nov 5, 2026
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Oct 30, 2026
Closed $1.08 (-4.4%) on Nov 2, 2026
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Oct 29, 2026
Closed $1.02 (0.0%) on Oct 29, 2026
Annovis to Attend the CTAD 2026 with Three Presentations
Oct 22, 2026
Closed $0.99 (0.0%) on Oct 22, 2026
Annovis Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 35 in the last 12 months · 58 in all · newest Nov 20, 2026 · oldest 2025
- Decks
- 11 decks · latest Jan 28, 2026
Where Annovis Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:ANVS · Home listing · This page | NYSE | United States | USD |
| LS Exchange:A2PNH2 | LS Exchange | Germany | EUR |
| gettex:07X | gettex | Germany | EUR |
| Lang & Schwarz:A2PNH2 | Lang & Schwarz | Germany | EUR |
| BOATS:ANVS | BOATS | United States | USD |
| Dusseldorf:07X | Dusseldorf | Germany | EUR |
| Frankfurt:07X | Frankfurt | Germany | EUR |
| Munich:07X | Munich | Germany | EUR |
| Stuttgart:07X | Stuttgart | Germany | EUR |
| Tradegate:07X | Tradegate | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $41.30M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 2.53
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Annovis Bio, Inc. · NYSE:ANVS | US$44.12M | US$41.30M | n/a | n/a | n/a | n/a | n/a | n/a | 2.53 |
| SunBio, Inc. · KRX:067370 | US$45.82M | US$42.92M | 14.2× | 4.6× | 8.9× | 2.0× | 34.6% | 0.0× | n/a |
| Apollomics Inc. · NASDAQ:APLM | US$45.28M | US$42.65M | n/a | 5.0× | n/a | n/a | −128.7% | n/a | 1.02 |
| Zelluna ASA · OSL:ZLNA | US$45.02M | US$38.83M | n/a | n/a | n/a | 5.1× | n/a | 0.0× | n/a |
| Oncoinvent ASA · OSL:ONCIN | US$44.76M | US$33.80M | n/a | 14.3× | n/a | 5.4× | −673.1% | 0.0× | n/a |
| Gain Therapeutics, Inc. · NASDAQ:GANX | US$44.50M | US$33.11M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.60 |
| ImageneBio, Inc. · NASDAQ:IMA | US$44.50M | −US$80.79M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.52 |
| Arch Biopartners, Inc. · TSXV:ARCH | US$44.06M | US$44.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.94 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Median of the others | US$44.50M | US$33.46M | 14.2× | 4.8× | 8.9× | 3.2× | −99.9% | 0.0× | 1.31 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.45 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Eve Damiano | Senior VP, Regulatory Operations |
| Michael Christie | VP, Process Chemistry |
| SARAH MacCALLUM | VP, Clinical Operations |
| Cheng Fang | CSO, Research and Development |
Board
| Director | Role |
|---|---|
| Michael B. Hoffman | Chairman of the Board |
| Claudine E. Bruck | Board Member |
| Maria L. Maccecchini | Executive Board Member |
| Mark White | Board Member |
| REID S. McCARTHY | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | +9.3% |
| Q2 2026 | Aug 14, 2026 · Before open | +3.4% |
| Q1 2026 | May 15, 2026 · Before open | −3.3% |
| Q4 2025 | Mar 23, 2026 | −8.8% |
| Q3 2025 | Nov 12, 2025 · Before open | +15.2% |
| Q2 2025 | Aug 12, 2025 · After close | −2.5% |
| Q1 2025 | May 8, 2025 · After close | −4.4% |
| Q4 2024 | Mar 21, 2025 · After close | +5.7% |
| Q3 2024 | Nov 8, 2024 · After close | −6.3% |
| Q2 2024 | Aug 14, 2024 · After close | +14.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | +15.5% |
| Q4 2023 | Mar 29, 2024 · After close | +0.5% |
| Q3 2023 | Nov 8, 2023 · After close | +4.3% |
| Q2 2023 | Aug 14, 2023 · After close | −2.5% |
| Q1 2023 | May 10, 2023 · After close | −0.8% |
| Q4 2022 | Mar 1, 2023 | −5.3% |
| Q3 2022 | Nov 8, 2022 · After close | −3.3% |
| Q2 2022 | Aug 8, 2022 · After close | +2.6% |
| Q1 2022 | May 4, 2022 · After close | −3.7% |
| Q4 2021 | Mar 2, 2022 · After close | −6.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (January 2026) | Corporate update | 26 slides | Jan 28, 2026 |
| Corporate Update (December 2024) | Corporate update | 23 slides | Dec 11, 2024 |
| Corporate Update (June 2024) | Corporate update | 15 slides | Jun 11, 2024 |
| Investor Presentation (February 2023) | Investor deck | 28 slides | Feb 13, 2023 |
| Investor Presentation (January 2023) | Investor deck | 27 slides | Jan 6, 2023 |
| Corporate Update (October 2021) | Corporate update | 12 slides | Oct 5, 2021 |
| AAIC Panel 2021 | Conference | 20 slides | Jul 29, 2021 |
| IPO Roadshow (May 2021) | IPO roadshow | 25 slides | May 21, 2021 |
| Investor Presentation (March 2021) | Investor deck | 26 slides | Mar 23, 2021 |
| Investor Presentation (June 2020) | Investor deck | 24 slides | Jun 9, 2020 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (December 2019) | IPO roadshow | 24 slides | Dec 10, 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock (or pre-funded warrants) and accompanying warrants Closed: US$21M raised · US$1 a share · Warrants at US$1 for 60 months · Canaccord Genuity Dealers: Canaccord Genuity (lead) Buyers: Chairman of the Board ($5.00 million, approximately 24% of the offering) Insiders: The Chairman of the Board contributed $5.00 million, approximately 24% of the offering Use of proceeds: Fund operations through the pivotal Phase 3 AD data readout and continued clinical development of buntanetap in AD and PD | Nov 9, 2026 |
| Public offering of underwritten public offering Closed: US$10M in the latest tranche · US$1.9 a share · Warrants at US$2.5 for 66 months · Canaccord Genuity Dealers: Canaccord Genuity (lead) Use of proceeds: Primarily to advance buntanetap through the pivotal Phase 3 Alzheimer's disease trial | Apr 13, 2026 |
| Registered direct offering of shares of common stock Announced: about US$3.4M · US$2.05 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Michael Hoffman; Dr. Maria Maccecchini Insiders: Participation of Chairman Michael Hoffman and CEO Dr. Maria Maccecchini Use of proceeds: Working capital and general corporate purposes | Oct 27, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) Closed: US$6M raised · US$1.5 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Oct 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.00 a share on Jan 29, 2020.
- Price
- US$6.00 a share
- Shares offered
- 2,000,000 shares of common stock
- Offering size
- US$12 million
- Underwriters' option
- Up to 300,000 more shares
- Listing
- ANVS on NYSE American
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Jan 31, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 15, 2019 |
| Filed publicly | Jul 3, 2019 |
| Amended 6 times | Newest Jan 24, 2020 |
| Shares registered with an exchange | Jan 28, 2020 |
| Declared effective by the SEC | Jan 28, 2020 |
| Final prospectus, with the price | Jan 30, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 30, 2020 |
| S-1MEF · Registration of more shares for the same offering | Jan 29, 2020 |
| EFFECT · Notice that a registration is effective | Jan 28, 2020 |
| CERT · Exchange's certificate of listing | Jan 28, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 28, 2020 |
| CORRESP · Letter to the SEC | Jan 24, 2020 |
| CORRESP · Letter to the SEC | Jan 24, 2020 |
| S-1/A · Registration statement, amended | Jan 24, 2020 |
| S-1/A · Registration statement, amended | Jan 21, 2020 |
| FWP · Free writing prospectus | Dec 10, 2019 |
All 28 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Nov 19, 2019 |
| CORRESP · Letter to the SEC | Sep 20, 2019 |
| S-1/A · Registration statement, amended | Sep 20, 2019 |
| UPLOAD · Letter from the SEC | Sep 10, 2019 |
| S-1/A · Registration statement, amended | Aug 28, 2019 |
| CORRESP · Letter to the SEC | Aug 27, 2019 |
| UPLOAD · Letter from the SEC | Aug 20, 2019 |
| S-1/A · Registration statement, amended | Aug 8, 2019 |
| CORRESP · Letter to the SEC | Aug 8, 2019 |
| UPLOAD · Letter from the SEC | Jul 15, 2019 |
| S-1 · Registration statement | Jul 3, 2019 |
| CORRESP · Letter to the SEC | Jul 2, 2019 |
| UPLOAD · Letter from the SEC | Jun 21, 2019 |
| UPLOAD · Letter from the SEC | Jun 6, 2019 |
| DRSLTR · Letter to the SEC with a draft | May 24, 2019 |
| DRS/A · Draft registration statement, amended | May 24, 2019 |
| DRSLTR · Letter to the SEC with a draft | May 15, 2019 |
| DRS · Draft registration statement | May 15, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 30, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185.2K |
| Cost of revenue | 11.5K | |||||||||
| Gross profit | 173.7K | |||||||||
| Research and development | 25.2M | 20.0M | 38.8M | 16.5M | 8.48M | 3.05M | 776.3K | 111.6K | 273.4K | |
| Selling, general and administrative | 4.48M | 6.70M | 6.24M | 9.00M | 6.06M | 3.59M | 829.4K | 602.3K | 409.1K | 1.95M |
| Operating income | -29.7M | -26.7M | -45.0M | -25.5M | -14.5M | -6.64M | -1.61M | -713.9K | -682.4K | -1.77M |
| Depreciation and amortization | 1 | 25.5K | 14.5M | 6.64M | 1.61M | 713.9K | 682.4K | 14.8K | ||
| EBITDA | -45.0M | -25.5M | -221 | 0 | 0 | 0 | 0 | -1.76M | ||
| Interest expense | 1.85M | 182.7K | 13.3K | 47.2M | 40.9M | 66 | 84 | 0 | ||
| Income before tax | -28.9M | -24.6M | -56.2M | -25.3M | -14.5M | -5.46M | -991.0K | -713.9K | -682.3K | -1.69M |
| Income tax | 0 | -24.6B | -45.0K | -182.7K | -50.1K | -1.21M | 0 | -132 | -682.4K | 0 |
| Net income | -28.9M | -24.6M | -56.2M | -25.3M | -14.5M | -5.46M | -991.0K | -713.9K | -682.3K | -8.32M |
| Earnings per share, basic | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 | -0.10 | -0.10 | |
| Earnings per share, diluted | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 19.5M | 10.6M | 5.75M | 28.4M | 45.7M | 8.07M | 1.86K | 35.3K | 347.5K | 72.3K |
| Short-term investments | 10.5B | |||||||||
| Receivables | 735.1K | 1.47M | ||||||||
| Inventory | -745.6M | 22.8K | ||||||||
| Current assets | 21.1M | 13.9M | 10.2M | 36.0M | 46.0M | 8.12M | 747.5K | 51.0K | 358.0K | 1.59M |
| Property, plant and equipment | 65.1K | |||||||||
| Total assets | 21.1M | 13.9M | 10.2M | 36.0M | 46.0M | 8.12M | 1.12M | 51.0K | 358.0K | 2.84M |
| Accounts payable | 2.59M | 2.31M | 1.29M | 3.96M | 688.1K | 341.9K | 1.23M | 68.4K | 71.1K | 174.4K |
| Current liabilities | 3.64M | 3.88M | 4.28M | 7.70M | 1.51M | 578.4K | 2.01M | 567.9K | 490.2K | 174.4K |
| Long-term debt | 499.8K | |||||||||
| Total debt | 499.8K | |||||||||
| Total liabilities | 4.23M | 4.62M | 18.0M | 7.70M | 1.51M | 578.4K | 2.62M | 7.64M | 7.32M | 174.4K |
| Shareholders' equity | 16.9M | 9.31M | -7.75M | 28.3M | 44.5M | 7.54M | -8.58M | -7.59M | -6.97M | 2.66M |
| Shares outstanding | 27.2M | 14.1M | 10.5M | 8.16M | 8.10M | 6.89M | 282.6K | 6.82M | 6.82M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -25.6M | -21.9M | -40.0M | -17.3M | -9.13M | -3.97M | -476.5K | -558.6K | -537.5K | -1.41M |
| Capital spending | 0 | -4 | -4 | -4 | 0 | -3 | 0 | 0 | 0 | -79.6K |
| Free cash flow | -25.6M | -21.9M | -40.0M | -17.3M | -9.13M | -3.97M | -476.5K | -558.6K | -537.5K | -1.49M |
| Cash from investing | -82.0K | |||||||||
| Cash from financing | 34.6M | 26.7M | 17.3M | 4.61K | 46.7M | 12.0M | 443.1K | 246.4K | 332.5K | 177.7K |
| Share buybacks | 46.7M | 12.0M | 246.4K | 332.5K | 1.29K | |||||
| Change in cash | 8.98M | 4.80M | -22.6M | -17.3M | 37.6M | 8.07M | -33.5K | -312.2K | -205.0K | -1.32M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 8-K · Current report | Nov 4, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Oct 30, 2026 | Current report | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 15, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 7, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 11, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 24, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 9, 2026 | Current report | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 20, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 20, 2026 | Offer document | SEC |
| 424B5 · Prospectus | May 19, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 9, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 25, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 28, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 14, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 30, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 29, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 19, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 20, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 16, 2025 | Insider trade | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | May 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 21, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| 8-K · Current report | Feb 4, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 4, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 3, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| 8-K · Current report | Dec 11, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 11, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 9, 2024 | Management or board change | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 8-K · Current report | Aug 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Current report | SEC |
| 8-K · Current report | Jul 16, 2024 | Current report | SEC |
| 8-K · Current report | Jul 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 21, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 11, 2024 | Current report | SEC |
| 8-K · Current report | Jun 5, 2024 | Current report | SEC |
| 8-K · Current report | May 21, 2024 | Current report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | May 6, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 6, 2024 | Current report | SEC |
| 8-K · Current report | May 2, 2024 | Current report | SEC |
| 8-K · Current report | May 1, 2024 | Management or board change | SEC |
| 424B5 · Prospectus | May 1, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 26, 2024 | Material contract | SEC |
| 8-K · Current report | Apr 2, 2024 | Results | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 21, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 21, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 20, 2024 | Current report | SEC |
| 8-K · Current report | Mar 19, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 18, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Mar 18, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 15, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Feb 13, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Feb 12, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 5, 2024 | Other filings | SEC |
| S-3 · Registration statement | Feb 1, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 28, 2023 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Nov 22, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 22, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 22, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 22, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 22, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 8, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 1, 2023 | Results | SEC |
| 424B5 · Prospectus | Nov 1, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Oct 30, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2023 | Current report | SEC |
| 8-K · Current report | Oct 12, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jun 16, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 2, 2023 | Meeting notice | SEC |
| 8-K · Current report | May 30, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 26, 2023 | Insider trade | SEC |
| D | Apr 24, 2023 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 4, 2023 | Current report | SEC |
| 8-K · Current report | Apr 3, 2023 | Material contract | SEC |
| 8-K · Current report | Apr 3, 2023 | Results | SEC |
| 424B5 · Prospectus | Mar 31, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2023 | Current report | SEC |
| 8-K · Current report | Mar 6, 2023 | Current report | SEC |
| 8-K · Current report | Feb 13, 2023 | Current report | SEC |
| 4 · Change in ownership | Feb 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Sep 12, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Aug 31, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 31, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 30, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2022 | Results | SEC |
| 8-K · Current report | Jun 3, 2022 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 4, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2022 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2022 | Meeting notice | SEC |
| 10-K · Annual report | Mar 2, 2022 | Annual report | SEC |
| 4 · Change in ownership | Jan 18, 2022 | Insider trade | SEC |
This page holds 200 of 317 filings. Open Filings
Cap table
Built by 6ix from Annovis Bio, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 62,022,520
- Fully diluted
- 62,022,520
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 62,022,520 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.00 · expire about Nov 2031 |
| Warrants · US$2.50 · expire about Oct 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 62,022,520 |
| Sep 30, 2026 | 42,686,201 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert M Whelan Jr Other companies: iAnthus Capital Holdings, Inc. (Director · Feb 5, 2021 – Feb 5, 2021 · Past); Aspen Technology Inc (Director · May 4, 2011 – Mar 11, 2025 · Past); Ariad Pharmaceuticals Inc (Director · Apr 12, 2010 – Jan 31, 2014 · Past) | Director · Jan 28, 2020 – Jul 1, 2020 · Past |
| Cheng Fang | CSO, Research and Development · Since at least Oct 22, 2026 |
| Claudine E. Bruck | Director · Since at least Jul 7, 2021 |
| Eve Damiano | Senior VP, Regulatory Operations · Since at least Sep 24, 2026 |
| Maria L. Maccecchini | Executive Board Member · Since at least Oct 29, 2026 |
| Mark White | Board Member · Since at least Nov 17, 2023 |
| Michael B. Hoffman | Director · Since at least Apr 2, 2026 |
| Michael Christie | VP, Process Chemistry · Since at least Nov 4, 2026 |
| REID S. McCARTHY | Director · Since at least Jun 10, 2025 |
| SARAH MacCALLUM | VP, Clinical Operations · Since at least Jul 7, 2026 |
Log in to ask 6ix AI your own questions about Annovis Bio, Inc.